In this week’s EuroBiotech Report, GW Pharmaceuticals is once again turning to U.S. investors to fuel the advance of its cannabis-based pipeline. The latest offering could generate upward of $180 million (€161 million), a sum that will give GW the firepower to mount a multi-front R&D program. And more.

…read more

Source: GW to raise $179M, KDEV’s portfolio value sinks to new low, BIA wants U.K. to rival CA, MA


0 No comments